Want to see SE:ALZCUR full AI Analyst Report?
Top Page
AlzeCure Pharma AB
(ALZCUR)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr8.50
▲(248.36% Upside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance (no revenue, large losses, and substantial ongoing cash burn with declining equity), implying continued funding dependence. Technicals are a supportive offset with the stock above major moving averages and non-overbought momentum, while valuation is less supportive due to a high P/E and no dividend yield data.
Positive Factors
Low financial leverage
Debt remains modest relative to the stated equity base, which limits direct balance-sheet leverage and interest-related pressure. This gives AlzeCure comparatively more flexibility to direct resources toward research programs and manage financing decisions while advancing its pipeline.
Negative Factors
No commercial revenue
The absence of reported revenue means the company has not yet established a commercial income stream to support its research organization. Financial progress therefore remains dependent on successful clinical development, future partnerships, or other funding rather than recurring product sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Debt remains modest relative to the stated equity base, which limits direct balance-sheet leverage and interest-related pressure. This gives AlzeCure comparatively more flexibility to direct resources toward research programs and manage financing decisions while advancing its pipeline.
Read all positive factors
AlzeCure Pharma AB (ALZCUR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.05B
Dividend YieldN/A
Average Volume (3M)451.93K
Price to Earnings (P/E)50.4
Beta (1Y)0.21
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding137,897,340
10 Day Avg. Volume261,604
30 Day Avg. Volume451,927
Financial Highlights & Ratios
PEG Ratio-1.96
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
AlzeCure Pharma AB Business Overview & Revenue Model
Company Description
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates b...
How the Company Makes Money
AlzeCure Pharma AB’s business model is typical of an early-stage biotech/pharma R&D company: it primarily creates value by discovering and developing drug candidates and then seeking to monetize them through partnering transactions and, potentiall...
AlzeCure Pharma AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -946.00K | -1.27M | -293.00K | -476.00K | -570.00K | -576.00K |
| EBITDA | -61.79M | -48.10M | -35.70M | -37.87M | -55.67M | -77.20M |
| Net Income | -59.20M | -47.65M | -35.23M | -37.17M | -56.04M | -77.78M |
Balance Sheet | ||||||
| Total Assets | 40.81M | 59.04M | 34.44M | 32.00M | 70.84M | 45.65M |
| Cash, Cash Equivalents and Short-Term Investments | 32.97M | 50.34M | 31.50M | 29.10M | 25.58M | 41.74M |
| Total Debt | 2.29M | 5.12M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 29.58M | 26.12M | 8.25M | 8.23M | 10.35M | 12.67M |
| Stockholders Equity | 11.23M | 32.92M | 26.18M | 23.77M | 60.48M | 32.97M |
Cash Flow | ||||||
| Free Cash Flow | -41.00M | -34.59M | -35.25M | 3.06M | -99.91M | -70.69M |
| Operating Cash Flow | -41.00M | -34.59M | -35.12M | 3.06M | -99.91M | -70.64M |
| Investing Cash Flow | 0.00 | 0.00 | -124.00K | 7.00K | 0.00 | -54.00K |
| Financing Cash Flow | 53.15M | 53.43M | 37.65M | 459.00K | 83.75M | 0.00 |
AlzeCure Pharma AB Technical Analysis
Positive
2.44
Price Trends
7.08
Positive
5.20
Positive
3.40
Positive
Market Momentum
0.17
Positive
50.32
Neutral
17.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZCUR, the sentiment is Positive. The current price of 2.44 is below the 20-day moving average (MA) of 7.93, below the 50-day MA of 7.08, and below the 200-day MA of 3.40, indicating a neutral trend. The MACD of 0.17 indicates Positive momentum. The RSI at 50.32 is Neutral, neither overbought nor oversold. The STOCH value of 17.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALZCUR.
AlzeCure Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | kr37.94B | 54.83 | 15.54% | ― | <0.01% | -6.75% | |
69 Neutral | kr29.04B | 270.59 | 5.18% | 0.67% | -46.09% | -90.13% | |
64 Neutral | kr1.39B | 7.39 | 29.71% | ― | 24.98% | -31.44% | |
52 Neutral | kr257.27M | -2.76 | -97.06% | ― | 4.74% | 66.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.05B | 50.37 | 65.99% | ― | ― | ― | |
44 Neutral | kr130.34M | -2.02 | -17.52% | ― | -100.00% | 20.94% |
* Healthcare Sector Average
SE:ALZCUR
AlzeCure Pharma AB
7.56
5.25
226.99%
SE:CAMX
Camurus AB
616.00
-50.50
-7.58%
SE:ALZ
Alzinova AB
0.41
-0.77
-65.15%
SE:BIOA.B
BioArctic AB Class B
318.40
29.31
10.14%
SE:SANION
Saniona AB
9.82
-2.10
-17.62%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.83
-1.13
-38.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.